Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Epigenetic reprogramming of stem cells

Andreas Trumpp, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses findings of recent stem cell research at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. A metabolic enzyme involved in the degradation and catabolism of branch chain amino acids and the epigenetic reprogramming of a cell has been discovered. There is ongoing research to find inhibitors to block this enzyme, therefore preventing the cell from becoming leukaemic.